FDA Roundup: August 29, 2023

News provided by

Aug 29, 2023, 14:55 ET

SILVER SPRING, Md., Aug. 29, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

On Monday, the FDA informed consumers in Treating and Dealing with ADHD about FDA-approved treatments to help reduce the symptoms of attention-deficit/hyperactivity disorder, also known as ADHD, and improve functioning in children as young as age 6 years old.

On Friday, the American Dental Association Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania School of Dental Medicine issued a new clinical practice guideline detailing dental pain management strategies for children. The development of this guideline was funded by an FDA-provided grant. An FDA-commissioned report by the National Academies of Science, Engineering, and Medicine recommended that the guideline be developed.

On Friday, the Interagency Food Safety Analytics Collaboration (IFSAC) — a collaboration between the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and the USDA Food Safety and Inspection Service (FSIS) — published its upcoming priorities for calendar years 2024 - 2028.

Additional Resources:

FDA Newsroom

Media Contact: FDA Office of Media Affairs, 301-796-4540
Consumer Inquiries: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

SOURCE U.S. Food and Drug Administration